Phase 2 Multiple Sclerosis Trial, Recruiting NCT06428006 Sponsor: University of Kansas Medical Center Condition: Multiple Sclerosis
Back to Multiple Sclerosis

Phase 2 Multiple Sclerosis Trial, Recruiting

NCT06428006
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People aged between 18 and 65 years old
  • People who have been diagnosed with relapsing-remitting or secondary progressive MS, confirmed by a neurologist
  • People with mild-to-moderate disability, scoring 6 or below on a scale called the Patient Determined Disability Steps (PDDS)
  • People who have had trouble falling asleep, staying asleep, or waking too early at least 3 nights per week for the past 3 months, where this causes significant distress or affects daily life, and is not caused by another sleep disorder
  • People who score 10 or higher on a sleep questionnaire called the Insomnia Severity Index
  • People who speak English
  • People who score 31 or higher on a phone-based cognitive assessment called the modified Telephone Interview of Cognitive Status
  • People who have completed high school or an equivalent qualification (used as an indicator of reading ability)
  • People who have access to internet service or a mobile data plan, and access to a computer, tablet, or smartphone

Who may not be able to join:

  • People who have a known but untreated sleep disorder, such as sleep apnea or restless legs syndrome
  • People who score above 3 on a screening tool called STOP BANG, which suggests a higher risk of sleep apnea
  • People identified as having restless legs syndrome based on a specific assessment tool
  • People identified as having a circadian rhythm sleep-wake disorder (a condition where the body clock is out of sync with normal sleep times) based on a specific questionnaire
  • People identified as having a parasomnia (unusual sleep behaviours such as sleepwalking) based on a specific questionnaire
  • People currently taking benzodiazepines, non-benzodiazepine sleep medications, or melatonin supplements or related medications for insomnia
  • People who score 20 or above on a depression questionnaire called the PHQ-9, indicating severe depression, or who report any level of suicidal thoughts on that questionnaire
  • People who score 15 or above on an anxiety questionnaire called the GAD-7, indicating severe anxiety
  • People with a current or recent history (within the past 2 years) of alcohol or drug misuse, as defined by standard diagnostic guidelines
  • People with a history of another nervous system condition, such as stroke or Parkinson's disease
  • People who are currently pregnant or planning to become pregnant within the next 6 months
  • People with a severe mental illness such as schizophrenia or bipolar disorder
  • People with severe neurological or sensory impairments that would significantly interfere with study testing
  • People who have had an MS relapse or used corticosteroid medications in the past 8 weeks
  • People who currently work overnight shifts, or have done so within the past 5 years, where those shifts include the hours of midnight to 4am
  • People who are currently taking part in another behavioural sleep health program or intervention

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: 913-945-7349

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
University of Kansas Medical Center
Registry
ClinicalTrials.gov
Start date
30 July 2024
Est. completion
31 May 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Insomnia Severity Index (ISI)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov